Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections
Objectives: Omiganan pentahydrochloride is a cidal cationic peptide with a broad antimicrobial spectrum, including yeast, currently in development as a topical agent for the prevention of catheter-associated infections. We evaluated the spectrum and potency of omiganan against pathogens commonly ass...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2008 |
| País: | Brasil |
| Recursos: | Universidade Federal de São Paulo (UNIFESP) |
| Repositorio: | Repositório Institucional da UNIFESP |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.unifesp.br:11600/30611 |
| Acesso em linha: | http://dx.doi.org/10.1093/jac/dkn074 http://repositorio.unifesp.br/handle/11600/30611 |
| Access Level: | acceso abierto |
| Palavra-chave: | cationic peptides topical antimicrobials resistance bloodstream infections |
| id |
BR_6d8d19e32aebaa7afad062ce2d21c5fd |
|---|---|
| oai_identifier_str |
oai:repositorio.unifesp.br:11600/30611 |
| network_acronym_str |
BR |
| network_name_str |
Brasil |
| repository_id_str |
|
| spelling |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infectionscationic peptidestopical antimicrobialsresistancebloodstream infectionsObjectives: Omiganan pentahydrochloride is a cidal cationic peptide with a broad antimicrobial spectrum, including yeast, currently in development as a topical agent for the prevention of catheter-associated infections. We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections.Methods: A recent (2005-06) collection of bacterial isolates originating from patients with bloodstream, respiratory tract, and skin and skin structure infections in US medical centres was evaluated by reference broth microdilution methods against omiganan and comparator agents.Results: All tested Gram-positive (390) and -negative (167) isolates were inhibited by <= 128 and <= 1024 mg/L, respectively, of omiganan. the agent was the most active against coagulase-negative staphylococci (range 1-8 mg/L; MIC50/90, 4 mg/L) and inhibited all Staphylococcus aureus at <= 32 mg/L (MIC50/90, 16 mg/L). Omiganan was 16-fold more active against Enterococcus faecium than Enterococcus faecalis (MIC50/90 results, 4/8 versus 64/128 mg/L, respectively). MIC ranges and MIC50 potencies were unaffected by methicillin resistance in staphylococci, vancomycin resistance in enterococci, and penicillin resistance in streptococci. Omiganan potency was also unaffected by extended-spectrum beta-lactamase (ESBL) production in Escherichia coli when compared with wild-type strains (MIC50 values 32 mg/L), although a 4-fold increase was noted among ESBL-positive Klebsiella spp. (128 versus 32 mg/L, respectively). Wild-type Enterobacter spp. displayed higher omiganan MIC50/90 results (64/512 mg/L) compared with AmpC-hyperproducing strains (32/64 mg/L). Carbapenem-susceptible and -resistant P. aeruginosa strains exhibited omiganan MIC50/90 values of 128/256 mg/L.Conclusions: At a 1% (10 000 mg/L) topical gel formulation, omiganan can be expected to inhibit all clinically relevant bacterial species producing catheter-associated infections (all MIC values, <= 1024 mg/L), including those with antimicrobial-resistant phenotypes.JMI Lab, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of ScienceOxford Univ PressJMI LabUniversidade Federal de São Paulo (UNIFESP)Tufts Univ2016-01-24T13:49:46Z2016-01-24T13:49:46Z2008-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1092-1098http://dx.doi.org/10.1093/jac/dkn074Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 61, n. 5, p. 1092-1098, 2008.10.1093/jac/dkn0740305-7453http://repositorio.unifesp.br/handle/11600/30611WOS:000254955300022ark:/48912/0013000023mxfengJournal of Antimicrobial Chemotherapyinfo:eu-repo/semantics/openAccesshttp://www.oxfordjournals.org/access_purchase/self-archiving_policyb.htmlreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPFritsche, Thomas R.Rhomberg, Paul R.Sader, Helio S. [UNIFESP]Jones, Ronald N.2016-01-24T11:49:46Zoai:repositorio.unifesp.br:11600/30611Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652016-01-24T11:49:46Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
| dc.title.none.fl_str_mv |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| title |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| spellingShingle |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections Fritsche, Thomas R. cationic peptides topical antimicrobials resistance bloodstream infections |
| title_short |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| title_full |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| title_fullStr |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| title_full_unstemmed |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| title_sort |
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections |
| dc.creator.none.fl_str_mv |
Fritsche, Thomas R. Rhomberg, Paul R. Sader, Helio S. [UNIFESP] Jones, Ronald N. |
| author |
Fritsche, Thomas R. |
| author_facet |
Fritsche, Thomas R. Rhomberg, Paul R. Sader, Helio S. [UNIFESP] Jones, Ronald N. |
| author_role |
author |
| author2 |
Rhomberg, Paul R. Sader, Helio S. [UNIFESP] Jones, Ronald N. |
| author2_role |
author author author |
| dc.contributor.none.fl_str_mv |
JMI Lab Universidade Federal de São Paulo (UNIFESP) Tufts Univ |
| dc.subject.por.fl_str_mv |
cationic peptides topical antimicrobials resistance bloodstream infections |
| topic |
cationic peptides topical antimicrobials resistance bloodstream infections |
| description |
Objectives: Omiganan pentahydrochloride is a cidal cationic peptide with a broad antimicrobial spectrum, including yeast, currently in development as a topical agent for the prevention of catheter-associated infections. We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections.Methods: A recent (2005-06) collection of bacterial isolates originating from patients with bloodstream, respiratory tract, and skin and skin structure infections in US medical centres was evaluated by reference broth microdilution methods against omiganan and comparator agents.Results: All tested Gram-positive (390) and -negative (167) isolates were inhibited by <= 128 and <= 1024 mg/L, respectively, of omiganan. the agent was the most active against coagulase-negative staphylococci (range 1-8 mg/L; MIC50/90, 4 mg/L) and inhibited all Staphylococcus aureus at <= 32 mg/L (MIC50/90, 16 mg/L). Omiganan was 16-fold more active against Enterococcus faecium than Enterococcus faecalis (MIC50/90 results, 4/8 versus 64/128 mg/L, respectively). MIC ranges and MIC50 potencies were unaffected by methicillin resistance in staphylococci, vancomycin resistance in enterococci, and penicillin resistance in streptococci. Omiganan potency was also unaffected by extended-spectrum beta-lactamase (ESBL) production in Escherichia coli when compared with wild-type strains (MIC50 values 32 mg/L), although a 4-fold increase was noted among ESBL-positive Klebsiella spp. (128 versus 32 mg/L, respectively). Wild-type Enterobacter spp. displayed higher omiganan MIC50/90 results (64/512 mg/L) compared with AmpC-hyperproducing strains (32/64 mg/L). Carbapenem-susceptible and -resistant P. aeruginosa strains exhibited omiganan MIC50/90 values of 128/256 mg/L.Conclusions: At a 1% (10 000 mg/L) topical gel formulation, omiganan can be expected to inhibit all clinically relevant bacterial species producing catheter-associated infections (all MIC values, <= 1024 mg/L), including those with antimicrobial-resistant phenotypes. |
| publishDate |
2008 |
| dc.date.none.fl_str_mv |
2008-05-01 2016-01-24T13:49:46Z 2016-01-24T13:49:46Z |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1093/jac/dkn074 Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 61, n. 5, p. 1092-1098, 2008. 10.1093/jac/dkn074 0305-7453 http://repositorio.unifesp.br/handle/11600/30611 WOS:000254955300022 |
| dc.identifier.dark.fl_str_mv |
ark:/48912/0013000023mxf |
| url |
http://dx.doi.org/10.1093/jac/dkn074 http://repositorio.unifesp.br/handle/11600/30611 |
| identifier_str_mv |
Journal of Antimicrobial Chemotherapy. Oxford: Oxford Univ Press, v. 61, n. 5, p. 1092-1098, 2008. 10.1093/jac/dkn074 0305-7453 WOS:000254955300022 ark:/48912/0013000023mxf |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Journal of Antimicrobial Chemotherapy |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html |
| dc.format.none.fl_str_mv |
1092-1098 |
| dc.publisher.none.fl_str_mv |
Oxford Univ Press |
| publisher.none.fl_str_mv |
Oxford Univ Press |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
| instname_str |
Universidade Federal de São Paulo (UNIFESP) |
| instacron_str |
UNIFESP |
| institution |
UNIFESP |
| reponame_str |
Repositório Institucional da UNIFESP |
| collection |
Repositório Institucional da UNIFESP |
| repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
| repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
| _version_ |
1853670531830644736 |
| score |
15.198674 |